BioCryst Pharmaceuticals, Inc. (BCRX)
9.82
-0.05
(-0.51%)
USD |
NASDAQ |
Aug 28, 16:00
9.71
-0.11
(-1.12%)
After-Hours: 20:00
BioCryst Pharmaceuticals Free Cash Flow : 356.23M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 356.23M |
| March 31, 2026 | 293.05M |
| December 31, 2025 | 327.41M |
| September 30, 2025 | 47.64M |
| June 30, 2025 | 15.50M |
| March 31, 2025 | -27.01M |
| December 31, 2024 | -53.14M |
| September 30, 2024 | -58.08M |
| June 30, 2024 | -86.59M |
| March 31, 2024 | -103.95M |
| December 31, 2023 | -97.31M |
| September 30, 2023 | -112.21M |
| June 30, 2023 | -123.95M |
| March 31, 2023 | -132.67M |
| December 31, 2022 | -163.20M |
| September 30, 2022 | -172.39M |
| June 30, 2022 | -163.42M |
| March 31, 2022 | -161.64M |
| December 31, 2021 | -144.54M |
| September 30, 2021 | -155.77M |
| June 30, 2021 | -170.56M |
| March 31, 2021 | -175.44M |
| December 31, 2020 | -137.73M |
| September 30, 2020 | -103.46M |
| June 30, 2020 | -92.76M |
| Date | Value |
|---|---|
| March 31, 2020 | -86.23M |
| December 31, 2019 | -89.93M |
| September 30, 2019 | -103.49M |
| June 30, 2019 | -110.84M |
| March 31, 2019 | -100.33M |
| December 31, 2018 | -92.93M |
| September 30, 2018 | -79.48M |
| June 30, 2018 | -57.02M |
| March 31, 2018 | -52.63M |
| December 31, 2017 | -41.47M |
| September 30, 2017 | -36.69M |
| June 30, 2017 | -41.81M |
| March 31, 2017 | -45.14M |
| December 31, 2016 | -58.72M |
| September 30, 2016 | -71.74M |
| June 30, 2016 | -66.80M |
| March 31, 2016 | -36.05M |
| December 31, 2015 | -18.24M |
| September 30, 2015 | -13.32M |
| June 30, 2015 | -9.151M |
| March 31, 2015 | -33.98M |
| December 31, 2014 | -38.66M |
| September 30, 2014 | -29.22M |
| June 30, 2014 | -28.51M |
| March 31, 2014 | -24.33M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Amgen, Inc. | 10.18B |
| Vertex Pharmaceuticals, Inc. | 3.796B |
| Agenus, Inc. | -98.50M |
| Anika Therapeutics, Inc. | 0.562M |
| Imunon, Inc. | -15.18M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 103.98M |
| Cash from Investing (Quarterly) | -110.15M |
| Cash from Financing (Quarterly) | -10.79M |
| Free Cash Flow Per Share (Quarterly) | 0.3913 |
| Free Cash Flow to Equity (Quarterly) | 125.21M |
| Free Cash Flow to Firm (Quarterly) | 125.19M |
| Free Cash Flow Yield | 15.33% |